RxDoctor Payments Data

Matthew Deluca, MD

Neurology · Bloomfield, NJNPI 1982680302

Payments from drug & device makers

$3,805in general payments, 2019–2025

Across 277 payments — averaging $13.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Bristol Myers Squibb$511
  • E.r. Squibb & Sons, L.L.C.$346
  • Teva Pharmaceuticals USA, Inc.$294
  • MDD US Operations, LLC$211
  • Supernus Pharmaceuticals, Inc.$187
  • plus $584 from 15 others

What the payments were for

  • Speaking & faculty fees$281%
  • Food & beverage$3,34488%
  • Education$43311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,805 in reported general payments places this provider in the 55th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$109,124
Medicare patients
325
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab19$274,098
NuplazidPimavanserin Tartrate42$211,126
VumerityDiroximel Fumarate16$145,294
CopaxoneGlatiramer Acetate24$136,132
AustedoDeutetrabenazine16$52,070
XadagoSafinamide Mesylate36$42,331
RexultiBrexpiprazole25$38,785
NeuproRotigotine38$37,469
UbrelvyUbrogepant17$15,010
OxycontinOxycodone Hcl11$13,474
NuedextaDextromethorphan Hbr/Quinidine14$10,698
Ajovy SyringeFremanezumab-Vfrm11$8,054
HorizantGabapentin Enacarbil14$6,969
Dalfampridine ErDalfampridine35$6,837
Rasagiline Mesylate21$5,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$294$188,20340 claims
BiogenVumerity$58$145,29416 claims
AbbVieUbrelvy$27$15,01017 claims
Arbor Pharmaceuticals, Inc.Horizant$37$6,96914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 521 neurology providers in New Jersey.

Other neurology in Bloomfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →